Logo image
Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
Journal article   Open access   Peer reviewed

Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions

Manish Ora, Neetu Soni, Aftab Hasan Nazar, Manish Dixit, Rohit Singh, Savita Puri, Michael M Graham and Sanjay Gambhir
The Journal of nuclear medicine (1978), Vol.64(7), pp.1001-1008
07/01/2023
DOI: 10.2967/jnumed.123.265594
PMID: 37268422
url
https://doi.org/10.2967/jnumed.123.265594View
Published (Version of record) Open Access

Abstract

Metastatic malignancies have limited management strategies and variable treatment responses. Cancer cells develop beside and depend on the complex tumor microenvironment. Cancer-associated fibroblasts, with their complex interaction with tumor and immune cells, are involved in various steps of tumorigenesis, such as growth, invasion, metastasis, and treatment resistance. Prooncogenic cancer-associated fibroblasts emerged as attractive therapeutic targets. However, clinical trials have achieved suboptimal success. Fibroblast activation protein (FAP) inhibitor–based molecular imaging has shown encouraging results in cancer diagnosis, making them innovative targets for FAP inhibitor–based radionuclide therapies. This review summarizes the results of preclinical and clinical FAP-based radionuclide therapies. We will describe advances and FAP molecule modification in this novel therapy, as well as its dosimetry, safety profile, and efficacy. This summary may guide future research directions and optimize clinical decision-making in this emerging field.

Details

Logo image